Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-26 @ 4:05 AM
Study NCT ID:
NCT02296918
Status:
COMPLETED
Last Update Posted:
2025-12-19
First Post:
2014-11-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Sponsor:
Acerta Pharma BV
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-12-22
Start Date Type:
ACTUAL
Primary Completion Date:
2021-08-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-22
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-19
First Submit QC Date:
None
Study First Post Date:
2014-11-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-15
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED